Study concludes that medium/high dose of ASA not protective against CAA Worse outcomes with high-dose ASA Not randomised, therefore more severe cases may have been given higher dose of ASA Unbalanced number of subjects 
Retrospective cohort
Prevalence of CAA, length of hospital stay, fever ≥72 hours
All treated with IVIG (single dose 2 g/kg)
Paracetamol use not reported High-dose ASA (80-100 mg/kg/day) (n=315) vs low-dose ASA (3-5 mg/kg/day) (n=43) New CA aneurysm: 10.2% (20/196) What dose of aspirin should be used in the initial treatment of Kawasaki disease?
SCenariO
You are looking after a previously well child recently diagnosed with Kawasaki disease (KD). You start him on intravenous immunoglobulin (IVIG) and are about to start him on aspirin. Knowing the potential adverse effects of aspirin, you wonder whether low-dose aspirin is as effective as high-side aspirin to prevent coronary artery complications.
STruCTured CliniCal queSTiOn
In a child with KD (patient), is low-dose aspirin (intervention) as effective as high-dose aspirin (control) in reducing the risk of coronary artery complications (outcome) when used with IVIG.
SearCh STraTegy and OuTCOme
PubMed and Medline (Ovid, 1946-present) 
COmmenTary
To prevent coronary artery complications resulting from the acute inflammatory response in KD, treatment with IVIG 2 g/ kg as a single infusion is recommended. In the acute phase of KD, guidelines also recommend the use of varying doses of aspirin for its anti-inflammatory and antithrombotic (table 2). All six of the studies that met our criteria found no difference in the prevalence of coronary artery aneurysms (CAA) in patients treated with low-dose compared with high-dose aspirin. [1] [2] [3] [4] [5] [6] We found no relevant randomised controlled trials. Most studies compared outcomes in patients treated with different regimens in the same institutions (physician preference 2 4 6 or reason for choice of regimen not reported 5 ). The two most recent studies compared patients in institutions using different regimens over the same time period. 1 3 The use of aspirin in the acute phase of KD dates from before the use of a single high dose of IVIG became routine, following trials showing its effectiveness. 7 Aspirin inhibits both the cyclooxygenase enzyme (COX)-1 (gastric mucosa and platelet aggregation) and COX-2 (inflammation) pathways. However, due to its considerately more selective inhibition of COX-1, larger doses are required for its anti-inflammatory (COX-2) effects. 8 Two different high-dose 'anti-inflammatory' aspirin regimens have been used in KD. Concerns about adverse effects led to the use of a dose of 30-50 mg/kg/day (sometimes referred to as a 'moderate dose') in Europe and Japan rather than the 80-100 mg/kg/day dose used in the USA. Adverse effects of aspirin include hepatic toxicity, 9 gastritis and upper gastrointestinal bleeding, 10 sensorineural hearing loss 11 and Reye syndrome. 12 One argument for the higher dose is that therapeutic salicylate levels are difficult to achieve in the acute phase of KD due to impaired absorption from hypoalbuminaemia and increased renal excretion. 13 However, in the subacute phase, when albumin levels normalise, a larger binding capacity to unbound salicylate typically causes sudden rises in salicylate levels and associated increased risk of toxicity and adverse effects. 14 When high-dose 'anti-inflammatory' aspirin is used in the acute phase of KD, many guidelines recommend changing to low-dose aspirin after resolution of fever for its antiplatelet effects to prevent coronary artery thrombosis during the subacute and convalescent phases.
For some time, experts have argued that high-dose 'anti-inflammatory' aspirin is not necessary in the acute phase of KD as it adds little, if any, anti-inflammatory effect over and above that provided by IVIG, 15 16 and that the lack of additional benefit does not justify exposing patients to the risk of adverse effects from high-dose aspirin. Some guidelines therefore recommend low-dose (3-5 mg/kg/day) 'anti-thrombotic' aspirin from the start to avoid the risk of adverse effects of high-dose aspirin.
The studies in our review did not report adverse effects of aspirin. However, the risk of adverse effects, including minor bleeding complications and gastric discomfort, is dose-dependent. 8 17 18 Despite the growing evidence that the risk of using high-dose aspirin outweighs the benefit, guidelines from the UK, Japan and USA still recommend the initial use of high-dose 'anti-inflammatory' aspirin. Of note, the most recent AHA guidelines highlight there is no evidence that use of either moderate (30-50 mg/kg/day) or high-dose (80-100 mg/kg/day) aspirin reduces the risk of CAAs. Our review supports using low-dose (3-5 mg/kg/day) aspirin in the acute phase of KD.
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